Background/Aims: Dietary restriction of fermentable oligosaccharides, disaccharides, monosaccharides and polyols (FODMAPs) may relieve symptoms in patients with irritable bowel syndrome (IBS). We investigated whether this diet alters microbial fermentation, a process that may be involved in IBS symptom generation. Methods: Patients with IBS were included consecutively to participate in a 4-week FODMAP restricted diet. IBS symptoms were evaluated by using the IBS severity scoring system (IBS-SSS). Short-chain fatty acids (SCFAs) were analyzed in fecal samples before and after the dietary intervention, both at baseline and after in vitro fermentation for 24 h. Results: Sixty-three patients completed the study. Following the dietary intervention, IBS-SSS scores improved significantly (p < 0.0001). Total SCFA levels were reduced in fecal samples analyzed both at baseline (p = 0.005) and after in vitro fermentation for 24 h (p = 0.013). Following diet, baseline levels of acetic (p = 0.003) and n-butyric acids (p = 0.009) decreased, whereas 24 h levels of i-butyric (p = 0.003) and i-valeric acids (p = 0.003) increased. Fecal SCFA levels and IBS symptom scores were not correlated. Conclusion: Dietary FODMAP restriction markedly modulated fecal fermentation in patients with IBS. Saccharolytic fermentation decreased, while proteolytic fermentation increased, apparently independent of symptoms.

Journal Section:
Original Paper
Keywords:
Carbohydrates, Clinical nutrition, Functional gastrointestinal disorders, Gut microbiota, Short-chain fatty acids
1.
Lovell RM, Ford AC: Global prevalence of and risk factors for irritable bowel syndrome: a meta-analysis. Clin Gastroenterol Hepatol 2012;10:712-721.e4.
[PubMed]
https://doi.org/10.1016/j.cgh.2012.02.029
2.
Gibson PR, Varney J, Malakar S, Muir JG: Food components and irritable bowel syndrome. Gastroenterology 2015;148:1158-1174.e4.
[PubMed]
https://doi.org/10.1053/j.gastro.2015.02.005
3.
Staudacher HM, Irving PM, Lomer MC, Whelan K: Mechanisms and efficacy of dietary FODMAP restriction in IBS. Nat Rev Gastroenterol Hepatol 2014;11:256-266.
[PubMed]
https://doi.org/10.1038/nrgastro.2013.259
4.
Marsh A, Eslick EM, Eslick GD: Does a diet low in FODMAPs reduce symptoms associated with functional gastrointestinal disorders? A comprehensive systematic review and meta-analysis. Eur J Nutr 2016;55:897-906.
[PubMed]
https://doi.org/10.1007/s00394-015-0922-1
5.
Schmidt A, Strasburger J: Ueber die intestinale gährungsdyspepsie der erwachsenen (insufficienz der stärkeverdauung). Deutsch Arch Klin Med 1901;LXIX:570-605.
6.
Svartz N: Colitis fermentativa; in Nordisk Lærebog i Intern Medicin, Bind II. Copenhagen, Gyldendalske Boghandel - Nordisk Forlag, 1945.
7.
King TS, Elia M, Hunter JO: Abnormal colonic fermentation in irritable bowel syndrome. Lancet 1998;352:1187-1189.
[PubMed]
https://doi.org/10.1016/S0140-6736(98)02146-1
8.
Tana C, Umesaki Y, Imaoka A, Handa T, Kanazawa M, Fukudo S: Altered profiles of intestinal microbiota and organic acids may be the origin of symptoms in irritable bowel syndrome. Neurogastroenterol Motil 2010;22:512-515.e114-e115.
[PubMed]
https://doi.org/10.1111/j.1365-2982.2009.01427.x
9.
Tan J, McKenzie C, Potamitis M, Thorburn AN, Mackay CR, Macia L: The role of short-chain fatty acids in health and disease. Adv Immunol 2014;121:91-119.
[PubMed]
https://doi.org/10.1016/B978-0-12-800100-4.00003-9
10.
Valeur J, Undseth R, Berstad A: ‘Gahrungsdyspepsie' revisited. Am J Gastroenterol 2016;111:145-147.
[PubMed]
https://doi.org/10.1038/ajg.2015.361
11.
Tveito K, Brunborg C, Bratlie J, Askedal M, Sandvik L, Lundin KE, Skar V: Intestinal malabsorption of D-xylose: comparison of test modalities in patients with celiac disease. Scand J Gastroenterol 2010;45:1289-1294.
[PubMed]
https://doi.org/10.3109/00365521.2010.503969
12.
Longstreth GF, Thompson WG, Chey WD, Houghton LA, Mearin F, Spiller RC: Functional bowel disorders. Gastroenterology 2006;130:1480-1491.
[PubMed]
https://doi.org/10.1053/j.gastro.2005.11.061
13.
Gibson PR, Shepherd SJ: Evidence-based dietary management of functional gastrointestinal symptoms: the FODMAP approach. J Gastroenterol Hepatol 2010;25:252-258.
[PubMed]
https://doi.org/10.1111/j.1440-1746.2009.06149.x
14.
Francis CY, Morris J, Whorwell PJ: The irritable bowel severity scoring system: a simple method of monitoring irritable bowel syndrome and its progress. Aliment Pharmacol Ther 1997;11:395-402.
[PubMed]
https://doi.org/10.1046/j.1365-2036.1997.142318000.x
15.
Zijlstra JB, Beukema J, Wolthers BG, Byrne BM, Groen A, Dankert J: Pretreatment methods prior to gaschromatographic analysis of volatile fatty acids from faecal samples. Clin Chim Acta 1977;78:243-250.
[PubMed]
https://doi.org/10.1016/0009-8981(77)90312-6
16.
Hoverstad T, Fausa O, Bjorneklett A, Bohmer T: Short-chain fatty acids in the normal human feces. Scand J Gastroenterol 1984;19:375-381.
[PubMed]
17.
Tjellstrom B, Hogberg L, Stenhammar L, Magnusson KE, Midtvedt T, Norin E, Sundqvist T: Effect of exclusive enteral nutrition on gut microflora function in children with Crohn's disease. Scand J Gastroenterol 2012;47:1454-1459.
[PubMed]
https://doi.org/10.3109/00365521.2012.703234
18.
Topping DL, Clifton PM: Short-chain fatty acids and human colonic function: roles of resistant starch and nonstarch polysaccharides. Physiol Rev 2001;81:1031-1064.
[PubMed]
19.
Cherbut C: Motor effects of short-chain fatty acids and lactate in the gastrointestinal tract. Proc Nutr Soc 2003;62:95-99.
[PubMed]
https://doi.org/10.1079/PNS2002213
20.
Kannampalli P, Shaker R, Sengupta JN: Colonic butyrate-algesic or analgesic? Neurogastroenterol Motil 2011;23:975-979.
[PubMed]
https://doi.org/10.1111/j.1365-2982.2011.01775.x
21.
Meijer K, de Vos P, Priebe MG: Butyrate and other short-chain fatty acids as modulators of immunity: what relevance for health? Curr Opin Clin Nutr Metab Care 2010;13:715-721.
[PubMed]
https://doi.org/10.1097/MCO.0b013e32833eebe5
22.
Scharlau D, Borowicki A, Habermann N, Hofmann T, Klenow S, Miene C, Munjal U, Stein K, Glei M: Mechanisms of primary cancer prevention by butyrate and other products formed during gut flora-mediated fermentation of dietary fibre. Mutat Res 2009;682:39-53.
[PubMed]
https://doi.org/10.1016/j.mrrev.2009.04.001
23.
Prasanna JL, Deepthi B, Rao NR: Rectal drug delivery: a promising route for enhancing drug absorption. Asian J Res Pharm Sci 2012;2:143-149.
24.
Nohr MK, Egerod KL, Christiansen SH, Gille A, Offermanns S, Schwartz TW, Moller M: Expression of the short chain fatty acid receptor GPR41/FFAR3 in autonomic and somatic sensory ganglia. Neuroscience 2015;290:126-137.
[PubMed]
https://doi.org/10.1016/j.neuroscience.2015.01.040
25.
Born P, Bauch C, Ulm K, Kamereck K, Classen M, Scheppach W: Fecal bacterial activity in symptomatic carbohydrate malabsorption: effect on the fecal short-chain fatty acid ratio. Z Gastroenterol 2000;38:623-626.
[PubMed]
https://doi.org/10.1055/s-2000-7512
26.
Windey K, Houben E, Deroover L, Verbeke K: Contribution of colonic fermentation and fecal water toxicity to the pathophysiology of lactose-intolerance. Nutrients 2015;7:7505-7522.
[PubMed]
https://doi.org/10.3390/nu7095349
27.
Hanstock TL, Clayton EH, Li KM, Mallet PE: Anxiety and aggression associated with the fermentation of carbohydrates in the hindgut of rats. Physiol Behav 2004;82:357-368.
[PubMed]
https://doi.org/10.1016/j.physbeh.2004.04.002
28.
MacFabe DF, Cain DP, Rodriguez-Capote K, Franklin AE, Hoffman JE, Boon F, Taylor AR, Kavaliers M, Ossenkopp KP: Neurobiological effects of intraventricular propionic acid in rats: possible role of short chain fatty acids on the pathogenesis and characteristics of autism spectrum disorders. Behav Brain Res 2007;176:149-169.
[PubMed]
https://doi.org/10.1016/j.bbr.2006.07.025
29.
Winston J, Shenoy M, Medley D, Naniwadekar A, Pasricha PJ: The vanilloid receptor initiates and maintains colonic hypersensitivity induced by neonatal colon irritation in rats. Gastroenterology 2007;132:615-627.
[PubMed]
https://doi.org/10.1053/j.gastro.2006.11.014
30.
Bourdu S, Dapoigny M, Chapuy E, Artigue F, Vasson MP, Dechelotte P, Bommelaer G, Eschalier A, Ardid D: Rectal instillation of butyrate provides a novel clinically relevant model of noninflammatory colonic hypersensitivity in rats. Gastroenterology 2005;128:1996-2008.
[PubMed]
https://doi.org/10.1053/j.gastro.2005.03.082
31.
El Oufir L, Flourie B, Bruley des Varannes S, Barry JL, Cloarec D, Bornet F, Galmiche JP: Relations between transit time, fermentation products, and hydrogen consuming flora in healthy humans. Gut 1996;38:870-877.
[PubMed]
https://doi.org/10.1136/gut.38.6.870
32.
Nyangale EP, Mottram DS, Gibson GR: Gut microbial activity, implications for health and disease: the potential role of metabolite analysis. J Proteome Res 2012;11:5573-5585.
[PubMed]
https://doi.org/10.1021/pr300637d
33.
Yao CK, Muir JG, Gibson PR: Review article: insights into colonic protein fermentation, its modulation and potential health implications. Aliment Pharmacol Ther 2016;43:181-196.
[PubMed]
https://doi.org/10.1111/apt.13456
34.
Staudacher HM, Lomer MC, Anderson JL, Barrett JS, Muir JG, Irving PM, Whelan K: Fermentable carbohydrate restriction reduces luminal bifidobacteria and gastrointestinal symptoms in patients with irritable bowel syndrome. J Nutr 2012;142:1510-1518.
[PubMed]
https://doi.org/10.3945/jn.112.159285
35.
Halmos EP, Christophersen CT, Bird AR, Shepherd SJ, Gibson PR, Muir JG: Diets that differ in their FODMAP content alter the colonic luminal microenvironment. Gut 2015;64:93-100.
[PubMed]
https://doi.org/10.1136/gutjnl-2014-307264
36.
Valeur J, Norin E, Midtvedt T, Berstad A: Assessment of microbial fermentation products in fecal samples. Neurogastroenterol Motil 2010;22:1147.
[PubMed]
https://doi.org/10.1111/j.1365-2982.2010.01534.x
© 2016 S. Karger AG, Basel
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
2016
You do not currently have access to this content.